Nurix therapeutics announces closing of public offering of common stock and full exercise of underwriters' option to purchase additional shares

San francisco, march 09, 2021 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of $31.00 per share, which includes 675,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. the gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $160.4 million.
NRIX Ratings Summary
NRIX Quant Ranking